Genaissance Licenses HAP Data, Informatics to AstraZeneca | GenomeWeb

NEW YORK, Dec. 11 - Genaissance Pharmaceuticals has given AstraZeneca access to specific HAP markers and its DecoGen informatics platform to help the pharmaceutical firm bolster its drug-discovery efforts, Genaissance said on Tuesday.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.